MDFEM
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended.[1][2][3] The properties and effects of MDFEM in humans appear to be unknown.[1][2][3] The drug is a partial agonist of the serotonin 5-HT2A and 5-HT2B receptors and also shows other receptor interactions.[3] MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.[1][2][3]
-2,5-dimethoxyamphetamine.svg)
Other names4-(2,2-Difluoroethoxy)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2-difluoroethoxy)amphetamine
ATC code
- None
FormulaC13H19F2NO3
| |
| Clinical data | |
|---|---|
| Other names | 4-(2,2-Difluoroethoxy)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2,2-difluoroethoxy)amphetamine |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C13H19F2NO3 |
| Molar mass | 275.296 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
